~~<i id='8871A01549'><strike id='8871A01549'><tt id='8871A01549'><pre id='8871A01549'></pre></tt></strike></i>~~

Home» explore» hotspot

hotspot

author：leisure time 2025-09-29 04:32:40 Page View：67181

Venture capitalist Alexis Borisy Vanessa Leroy for STAT

EQRx is done, sold for its cash.

The once-buzzy but now dormant biotech company is being acquired by Revolution Medicines, a developer of cancer drugs, the companies announced Tuesday.

The all-stock deal is essentially a balance-sheet transfer of $1 billion in cash from EQRx to Revolution. What was left of EQRx’s drug pipeline is being shelved.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： PBMs are inflating the cost of generic drugs. They must be reined in
Next article： Moonlake's readout produced a cash windfall. Risks remain

Wikipedia

FDA approval of Sarepta Duchenne genetic therapy gives me hope

Duchennemusculardystrophyhistopathology.Dr.EdwinP.Ewing,Jr./CDCWhenIwasdiagnosedwithDuchennemuscular

Menendez indictment could see pharma lose a key ally

Sen.BobMenendez(D-N.J.)MichaelM.Santiago/GettyImagesWASHINGTON—WithmountingcallsforembattledSen.BobM

23andMe had bad news about my health. I wish a person had delivered it

ERICBARADAT/AFP/GettyImagesLastsummer,IthoughtitmightbefuntohavemyDNAanalyzed.Twocompanies,23andMean

Abortion policy in the spotlight at Republican debate

AlexHogan/STATYou’rereadingthewebeditionofD.C.Diagnosis.Signupheretoreceivethisnewsletterinyourinbox